Our broad pipeline includes five proprietary agents with differentiated mechanisms of action. Those in the most advanced stages of development are in the clinic to fight cancer and COVID-19.

Corvus Pipeline


Mupadolimab (CPI-006)

Mupadolimab is an anti-CD73 antibody that binds to various immune cells. By binding to CD73 it appears to inhibit production of immunosuppressive adenosine in the tumor microenvironment. In addition, mupadolimab has other distinct properties including effects on B cell function. Binding of mupadolimab to CD73 on B cells appears to result in their activation and subsequent trafficking to lymph nodes, differentiation into plasmablasts and secretion of antibodies.

Over 90 patients with a variety of cancers who have failed standard therapies have been treated with mupadolimab in a Phase 1/1b study evaluating it as a monotherapy and in combination with ciforadenant or pembrolizumab. Another cohort of the study is evaluating the triplet of mupadolimab, ciforadenant and pembrolizumab. In addition, Corvus has published results from the initial cohorts of its Phase 1 COVID-19 study which also includes pre-clinical data characterizing the novel immunotherapy approach with mupadolimab.

A common factor in patients where mupadolimab has shown activity is the presence of viral antigens. The induction of antibody secretion is antigen specific and appears to be dependent on exposure to antigens such as the SARS-CoV-2 virus, or in the case of patients with human papilloma virus positive (HPV+) head and neck cancer, exposure to HPV. Corvus is evaluating mupadolimab in combination with pembrolizumab in patients with advanced, HPV+ head and neck cancer. Head and neck cancer is increasing in incidence in the U.S. and many other cancers are believed to be associated with or caused by viruses.


CPI-818 was designed to be an oral, small molecule drug with dual properties: to block malignant T cell growth, and to modulate immune responses. It has been shown [in preclinical studies] to selectively inhibit ITK (interleukin-2-inducible T cell kinase), an enzyme expressed predominantly in T cells and that plays a role in T cell and natural killer (NK) cell lymphomas and leukemias, as well as in normal immune function. We believe inhibiting ITK may be of therapeutic benefit for patients with T-cell lymphomas, certain B cell lymphomas and those with solid tumors because of its potential immune-enhancing properties.

A Phase 1/1b clinical trial in patients with refractory T-cell lymphomas is in progress and a global Phase 2 clinical trial in the same patient population is planned in partnership with Angel Pharmaceuticals, a China-based, privately held biopharmaceutical company launched through a collaboration between Corvus and investors in China. This Phase 2 trial is expected to have the potential to expand into autoimmune and dermatological diseases over time.

Ciforadenant (CPI-444)

Corvus is a leader in the development of precisely targeted therapies targeting the adenosine pathway. Ciforadenant is a small molecule antagonist of the adenosine A2A receptor, a key step in the adenosine pathway leading to immunosuppression in the tumor microenvironment. By precisely targeting and blocking A2A receptors on immune cells, ciforadenant may unleash their cancer-killing properties. Ciforadenant and mupadolimab provide complementary approaches to a cancer immunotherapy approach via the adenosine pathway.

Results from a Phase 1/1b clinical trial demonstrated that ciforadenant was active alone and in combination with atezolizumab in patients with advanced, refractory renal cell cancer (Fong et al., Cancer Discovery 2020). The study also describes the Adenosine Gene Signature, a novel biomarker, which was found to be beneficial in identifying patients most likely to respond to therapy.

A Phase 2 clinical trial of ciforadenant in first-line therapy for metastatic renal cell cancer in combination with pembrolizumab and Lenvatinib is planned in collaboration with the Kidney Cancer Consortium.

For more information on our pipeline, please see our Annual Report available in the SEC Filings section of the website.

Our Science

We are developing immunology focused medicines that target the most critical cellular elements of the immune system

Join Our Team

Contribute your talent, expertise and desire to learn here at Corvus, where you can help improve the lives of people with cancer, immune disorders and infectious diseases